Clinical Trial: Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Randomized Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis at Federal District, Brazil
Brief Summary: The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.
Detailed Summary: Mucosal leishmaniasis is a rare form of the disease, that affects only 6% of the patients with cutaneous leishmaniasis in the New World. It causes deformities and may be lethal if not treated. It is part of the neglected tropical diseases because on the past sixty years there was few progress regarding other treatment options or improvement at quality of life of its patients. Also, there was little interest from the pharmaceutical industry and government authorities to develop new researches. The standard treatment, meglumine antimoniate, is toxic, invasive, requires trained personnel and has many adverse effects and restrictions. On the other hand, miltefosine is the first oral drug to demonstrate efficacy against mucocutaneous leishmaniasis. Few clinical trials have being performed in Central and South American countries, but so far, just one involved mucosal leishmaniasis patients, and compared miltefosine to amphotericin B. None studies comparing its efficacy to the standard treatment have being done.
Sponsor: Brasilia University Hospital
Current Primary Outcome: Cure [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Adverse effects [ Time Frame: 6 months ]
Original Secondary Outcome: Same as current
Information By: Brasilia University Hospital
Dates:
Date Received: June 20, 2011
Date Started: July 2009
Date Completion:
Last Updated: June 8, 2015
Last Verified: June 2015